Source: Baptist Press
BETHESDA, Md. (AP) — The first COVID-19 vaccine tested in the U.S. revved up people’s immune systems just the way scientists had hoped, researchers reported Tuesday — as the shots are poised to begin key final testing.
“No matter how you slice this, this is good news,” Dr. Anthony Fauci, the U.S. government’s top infectious disease expert, told The Associated Press.
The experimental l vaccine, developed by Fauci’s colleagues at the National Institutes of Health and Moderna Inc., will start its most important step around July 27: A 30,000-person study to prove if the shots really are strong enough to protect against the coronavirus.
But Tuesday, researchers reported anxiously awaited findings from the first 45 volunteers who rolled up their sleeves y hands” during a November 2018 protest over the results of the close gubernatorial election. “We need someone who is not afraid to put themselves on the line for their constituents in the same way that Congressman Lewis taught us to,” she added. The party’s executive committee overwhelmingly voted for Williams over several other candidates, who were nominated from a pool of more than 130 applicants. The other candidates were state Rep. Park Cannon, Atlanta council member Andre Dickens, former Morehouse College President Robert Franklin and Georgia NAACP President James “Major” Woodall. The Democratic nominee in the deep blue district is likely to win the race. back in March. Sure enough, the vaccine provided a hoped-for immune boost.
Those early volunteers developed what are called neutralizing antibodies in their bloodstream — molecules key to blocking infection — at levels comparable to those found in people who survived COVID-19, the research team reported in the New England Journal of Medicine.
“This is an essential building block that is needed to move forward with the trials that could actually determine whether the vaccine does protect against infection,” said Dr. Lisa Jackson of the Kaiser Permanente Washington Research Institute in Seattle, who led the study.
There’s no guarantee, but the government hopes to have results around the end of the year — record-setting speed for developing a vaccine.
The vaccine requires two doses, a month apart.
There were no serious side effects. But more than half the study participants reported flu-like reactions to the shots that aren’t uncommon with other vaccines — fatigue, headache, chills, fever and pain at the injection site. For three participants given the highest dose, those reactions were more severe; that dose isn’t being pursued.
Some of those reactions are similar to coronavirus symptoms but they’re temporary, lasting about a day and occur right after vaccination, researchers noted.
“Small price to pay for protection against COVID,” said Dr. William Schaffner of Vanderbilt University Medical Center, a vaccine expert who wasn’t involved with the study.
He called the early results “a good first step,” and is optimistic that final testing could deliver answers about whether it’s really safe and effective by the beginning of next year.